On June 7, 2017, IPHARMA had received the Ministry of Health of the Russian Federation permission to conduct a Phase I clinical trial of Testonorm®.
Protocol No. ANDR-TSN-01 "Double-blind, randomized, placebo-controlled study of the safety and tolerability of increasing doses of Testonorm® with single and subsequent multiple intramuscular injection in healthy volunteers."
The purpose of the clinical study: evaluate the safety profile and tolerability of the drug Testonorm® for a single and subsequent repeated administration to healthy volunteers.
Therapeutic area: urology.
The leading organization in the study is I.M.Sechenov First Moscow State Medical University